StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

4-((Dipropylamino)sulfonyl)-benzoesäure

Probenecid

HCID 4911
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
57-66-9
Standard-SMILES
CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1
InChIKey
DBABZHXKTCFAPX-UHFFFAOYSA-N
Summenformel
C13H19NO4S
Durchschnittliche Molmasse
285,36 g/mol
Monoisotopische Masse
285,10347926

Überblick

Probenecid appears as odorless white or almost white crystalline powder. Slightly bitter taste; pleasant aftertaste. (NTP, 1992)

Namen und Bezeichner

Bevorzugter Name
Probenecid
IUPAC
4-(dipropylsulfamoyl)benzoic acid
Lokaler Name
4-((Dipropylamino)sulfonyl)-benzoesäure
Englischer Name
Probenecid
Summenformel
C13H19NO4S
Molmasse
285.36

Namen und Synonyme

probenecid57-66-94-(Dipropylsulfamoyl)benzoic acidBenemidProbenecid acidProbecidBenecidApurinaBenurylp-(Dipropylsulfamoyl)benzoic acidProbalanProbenemid
Weitere Namen anzeigen
4-(N,N-Dipropylsulfamoyl)benzoic acidPROBENICIDBinghuangshu4-((dipropylamino)sulfonyl)-benzoicaci4-[(dipropylamino)sulphonyl]benzoic acidbenacen
ProlongineTubophanUricosidProbenSynergid RProbenecideProbenecidum4-[(dipropylamino)sulfonyl]benzoic acid

Datenbank-Bezeichner

CAS
57-66-9
PubChem CID
4911
DTXSID
DTXSID9021188
ChEMBL
CHEMBL897
ChEBI
CHEBI:8426
UNII
PO572Z7917
EC Number
200-344-3

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
3,2
Polarare Oberfläche (TPSA)
83,1 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
7
Schwere Atome
19
Formalladung
0
Komplexität
374

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

SpringerMaterials PropertiesCrystal structure
LogP · 2 Einträge

2.3

3.21

OdorPRACTICALLY ODORLESS
TasteSLIGHTLY BITTER; PLEASANT AFTERTASTE
Color/Form · 2 Einträge

CRYSTALS FROM DIL ALCOHOL

WHITE OR NEARLY WHITE, FINE, CRYSTALLINE POWDER

Solubility · 5 Einträge

less than 1 mg/mL at 68 °F (NTP, 1992)

FREELY SOL IN WATER /SODIUM SALT/

SOL IN DIL ALKALI, ALCOHOL, CHLOROFORM & ACETONE; PRACTICALLY INSOL IN WATER & DIL ACIDS

4.25e-01 g/L

>42.8 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 4 Einträge

Breast Feeding; Lactation; Antigout Agents; Gout Suppressants; Sulfonamides; Uricosuric Agents

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 81 reports by companies from 5 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Other Safety InformationIMAP assessments - Benzoic acid, 4-[(dipropylamino)sulfonyl]-: Environment tier I assessment
DOT LabelPoison
Fire HazardsFlash point data for this chemical are not available. It is probably combustible. (NTP, 1992)
Health Hazards · 1 Eintrag

SYMPTOMS: Symptoms of exposure to this chemical include nausea, vomiting, headache, sore gums, flushing, dizziness, urinary frequency and anemia. On rare occasions an anaphylactic reaction or a hypersensitivity reaction with fever, dermatitis and pruritis has occurred, and there have been reports of hepatic necrosis, the nephrotic syndrome and aplastic anemia. Exposure may precipitate an acute attack of gout, and renal colic or renal calculi with or without hematuria may occur. It may also cause gastrointestinal upset. Other symptoms include urticaria, nephrosis, coma and status epilepticus. In massive overdosage, stimulation of the central nervous system with convulsions and death from respiratory failure may occur. Exposure may also cause increased plasma concentrations of methotrexate, costovertebral pain, precipitation of acute gouty arthritis, anorexia, leukopenia, alopecia and hemolytic anemia (which could be related to genetic deficiency of glucose-6-phosphate dehydrogenase in red blood cells). It may also cause skin rashes. It may occasionally cause drug fever. Jaundice, asthma and eosinophilia have preceded a massive hepatic necrosis.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding75-95%
Pharmacodynamics · 1 Eintrag

Probenecid is a uricosuric and renal tubular blocking agent and is used in combination with colchicine to treat chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. It inhibits the reabsorption of urate at the proximal convoluted tubule, thus increasing the urinary excretion of uric acid and decreasing serum urate levels. Effective uricosuria reduces the miscible urate pool, retards urate deposition, and promotes resorption of urate deposits. At the proximal and distal tubles, probenecid competitively inhibits the secretion of many weak organic acids including penicillins, most cephalosporins, and some other β-lactam antibiotics. This results in an increase in the plasma concentrations of acidic drugs eliminated principally by renal secretion, but only a slight increase if the drug is eliminated mainly by filtration. Thus, the drug can be used for therapeutic advantages to increase concentrations of certain β-lactam antibiotics in the treatment of gonorrhea, neurosyphilis, or pelvic inflammatory disease (PID).

Mechanism of Action · 6 Einträge

Probenecid inhibits the tubular reabsorption of urate, thus increasing the urinary excretion of uric acid and decreasing serum urate levels. Probenecid may also reduce plasma binding of urate and inhibit renal secretion of uric acid at subtherapeutic concentrations. The mechanism by which probenecid inhibits renal tubular transport is not known, but the drug may inhibit transport enzymes that require a source of high energy phosphate bonds and/or nonspecifically interfere with substrate access to protein receptor sites on the kidney tubules.

IN HIGHER DOSES THAN ARE REQUIRED FOR URICOSURIC EFFECT, PROBENECID ALSO INHIBITS TRANSPORT OF ORG ACIDS AT OTHER SITES, IE, TRANSPORT SYSTEM THAT REMOVES ORG ACIDS FROM CEREBROSPINAL FLUID.

IT INHIBITS TUBULAR REABSORPTION OF URATE, THUS INCR URINARY EXCRETION OF URIC ACID & DECR SERUM URIC ACID LEVELS.

Probenecid is a renal tubular blocking agent. The drug competitively inhibits active reabsorption of uric acid at the proximal convoluted tubule, thus promoting urinary excretion of uric acid and reducing serum urate concentrations. Probenecid may reduce plasma protein binding of urate and, in subtherapeutic doses, may inhibit renal secretion of uric acid. In healthy individuals, probenecid has no effect on the glomerular filtration rate or on the tubular reabsorption of normal urinary constituents such as glucose, arginine, urea, sodium, potassium, chloride, or phosphate.

Zugehörige Reaktionen

7
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1060279
HRID 1060279als Edukt
Reaktionsgleichung von HRID 1062976
HRID 1062976als Edukt
Reaktionsgleichung von HRID 1143178
HRID 1143178als Edukt
Reaktionsgleichung von HRID 1151975
HRID 1151975als Edukt
Reaktionsgleichung von HRID 2187443
HRID 2187443als Edukt
Reaktionsgleichung von HRID 2250687
HRID 2250687als Edukt
Reaktionsgleichung von HRID 2308452
HRID 2308452als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Nikkaji
J1.382J

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

DecompositionWhen heated to decomposition it emits very toxic fumes of oxides of sulfur and oxides of nitrogen.
Melting Point · 3 Einträge

381 to 385 °F (NTP, 1992)

194-196 °C

195 °C

Physical Description · 2 Einträge

Probenecid appears as odorless white or almost white crystalline powder. Slightly bitter taste; pleasant aftertaste. (NTP, 1992)

Solid

Stability/Shelf Life · 1 Eintrag

Probenecid tablets should be stored in well closed containers at a temperature less than 40 °C, preferably between 15-30 °C. Commercially available preparations containing probenecid and colchicine should be protected from light. Following the date of manufacture, commercially available probenecid tablets have an expiration date of 3-5 yr depending on the packaging.

Physikochemische Eigenschaften

Schmelzpunkt
194 · 194-196°C
Siedepunkt
438 · 438.0±47.0 °C(Predicted)
Dichte
1.2483 · 1.2483 (rough estimate)
Brechungsindex
1.68 · 1.6800 (estimate)
storage temp.
Store at RT
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
5.8 · 5.8(at 25℃)
Farbe
White to Off-White
Wasserlöslichkeit
0.1 g/100 · <0.1 g/100 mL at 20 ºC
Merck
14 · 14,7754
Stabilität
Stable, but may be light sensitive. Incompatible with strong oxidizing agents.
InChI
1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)
InChIKey
DBABZHXKTCFAPX-UHFFFAOYSA-N
SMILES
CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O
CAS Datenbank
57 · 57-66-9(CAS DataBase Reference)
NIST chemische Informationen
P-(dipropylsulfamoyl) benzoic acid(57-66-9)
EPA chemische Informationen
Probenecid (57-66-9)
FDA Requirements · 2 Einträge

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl probenecid, approved on the basis of safety and effectiveness by FDA under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act.

Reactive GroupAcids, Carboxylic
Special ReportsDHHS/NTP; Toxicology & Carcinogenesis Studies of Probenecid in F344/N Rats and B6C3F1 Mice (Gavage Studies) Technical Report Series No. 395 (1991) NIH Publication No. 91-2850
Reactivity ProfilePROBENECID may be light sensitive (NTP, 1992).
Air and Water ReactionsInsoluble in water.
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Sicherheit und Schutzausrüstung

Fire FightingFires involving this material can be controlled using a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
First Aid · 1 Eintrag

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Nonfire Spill Response · 1 Eintrag

SMALL SPILLS AND LEAKAGE: If a spill of this chemical occurs, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with acetone and transfer the dampened material to a suitable container. Use absorbent paper dampened with acetone to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with acetone followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Isolation and EvacuationExcerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:
Personal Protective Equipment (PPE) · 1 Eintrag

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

Toxikologische Informationen

Interactions · 5 Einträge

PROBENECID INHIBITS RENAL TRANSPORT OF ... PANTOTHENIC ACID, IODOMETHAMATE & RELATED IODINATED ORG ACIDS, AMINOHIPPURIC ACID, 17-KETOSTEROIDS PHENOLSULFONPHTHALEIN & SULFOBROMOPHTHALEIN. DOSAGE OF THESE AGENTS ... SHOULD BE MODIFIED WHEN THEY ARE ADMIN WITH PROBENECID. ... /IT ALSO/ INCR RENAL EXCRETION OF OXIPURINOL ... .

CONCURRENT ADMIN OF CEPHALEXIN & PROBENECID RESULTS IN HIGHER & PROLONGED SERUM ANTIBIOTIC LEVELS. ... CONCURRENT THERAPY DOES NOT APPEAR TO HAVE ANY CLINICAL ADVANTAGE OVER INCR IN ANTIBIOTIC DOSE.

/IN ADDN TO CEPHALEXIN/ OTHER CEPHALOSPORIN ANALOGS WHOSE SERUM LEVELS ARE ENHANCED BY PROBENECID ARE CEFAZOLIN, CEPHACETRILE, CEPHALOGLYCIN, CEPHALORIDINE, CEPHALOTHIN & CEPHRADINE.

CONCURRENT ADMIN OF PROBENECID, PARTICULARLY IN HIGH DOSES, DECR RENAL CLEARANCE OF NITROFURANTOIN & INCR SERUM LEVEL. ... INTERACTION MAY LEAD TO NITROFURANTOIN-INDUCED TOXICITY (EG, POLYNEUROPATHIES) OR DECR NITROFURANTOIN EFFICACY AS URINARY TRACT ANTI-INFECTIVE AGENT.

For more Interactions (Complete) data for PROBENECID (55 total), please visit the HSDB record page.

Hepatotoxicity · 1 Eintrag

There are no reports on the frequency of liver test abnormalities during probenecid therapy, but they are probably rare as the drug is largely secreted unchanged in the urine. A single case report of a severe hypersensitivity reaction from probenecid and rechallenge with a rapid and severe recurrence of jaundice was reported over 50 years ago. As is typical for hypersensitivity reactions, the onset was within days of starting probenecid and was accompanied by fever and rash.

Ongoing Test Status · 1 Eintrag

The following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the "Standard Toxicology & Carcinogenesis Studies", "Developmental Studies", and "Genetic Toxicity Studies" performed with this chemical. Clicking on the "Testing Status" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical. [http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=57-66-9]

Human Toxicity Excerpts · 5 Einträge

HUGE OVERDOSAGE OF PROBENECID RESULTS IN STIMULATION OF CNS, CONVULSIONS, & DEATH FROM RESP FAILURE.

... /OCCASIONALLY/ PATIENTS MAY EXPERIENCE ANOREXIA, NAUSEA, VOMITING, URINARY FREQUENCY, HYPERSENSITIVITY REACTIONS, SORE GUMS, FLUSHING, DIZZINESS & ANEMIA. NEPHROTIC SYNDROME, HEPATIC NECROSIS & APLASTIC ANEMIA OCCUR RARELY.

The most frequent adverse effects include headache, anorexia, nausea, and vomiting. Other reported adverse effects include dizziness, flushing, sore gums, alopecia, urinary frequency, leukopenia, and anemia. Nephrotic syndrome, hepatic necrosis, and aplastic anemia occur rarely. Mild to moderately severe hemolytic anemia, which in some patients could be related to genetic deficiency of glucose-6-phosphate dehydrogenase, has also been reported.

Hypersensitivity reactions which may be characterized by dermatitis, pruritus, fever, sweating, hypotension, and anaphylactic reaction occur rarely. Most cases of severe allergic reactions and anaphylaxis have been reported to occur within several hours after administration in patients who had previously received the drug. If a hypersensitivity reaction occurs in patients receiving probenecid, the drug should be discontinued. If rash occurs during administration of penicillin with probenecid and the causative agent cannot be determined, discontinuance of both drugs may be necessary.

For more Human Toxicity Excerpts (Complete) data for PROBENECID (7 total), please visit the HSDB record page.

Carcinogen Classification · 6 Einträge

Probenecid

TR-395: Toxicology and Carcinogenesis Studies of Probenecid (CASRN 57-66-9) in F344/N Rats and B6C3F1 Mice (Gavage Studies) (1991 )

11/20/90

No Evidence

No Evidence

No Evidence

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Probenecid

Ambiguous-DILI-concern

6

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 3 Einträge

... /STUDIES HAVE SHOWN THAT PROBENECID BLOCKS/ THE TRANSPORT SYSTEM FOR ELIMINATION OF 5-HYDROXYINDOLEACETIC ACID (5HIAA) FROM BRAIN IN RATS.

Probenecid was tested for mutagenicity in the Salmonella/microsome preincubation assay using the standard protocol approved by the National Toxicology Program. Probenecid was tested at doses of 0.033, 0.10, 0.33, 1.0, and 3.3 mg/plate in as many as 5 Salmonella typhimurium strains (TA1535, TA1537, TA97, TA98, and TA100) in the presence and absence of rat or hamster liver S-9. Probenecid was negative in these tests and the highest ineffective dose tested in any Salmonella typhimurium strain mg/plate.

... Under the conditions of these 2 yr gavage studies, there was no evidence of carcinogenic activity of probenecid for male or female F344/N rats receiving 100 or 400 mg/kg in corn oil. There was no evidence of carcinogenic activity of probenecid for male B6C3F1 mice given 100 or 400 mg/kg probenecid in corn oil. There was some evidence of carcinogenic activity of probenecid for female B6C3F1 mice based on an increased incidence of hepatocellular adenomas.

Populations at Special Risk... /PROBENECID/ IS CONTRAINDICATED IN PATIENTS WITH HISTORY OF RENAL CALCULI, ESP URIC ACID STONES, BECAUSE IT MAY AGGRAVATE OR PRECIPITATE THIS CONDITION.
Antidote and Emergency TreatmentIn acute probenecid overdosage, it has been recommended that the stomach be emptied immediately by inducing emesis or by gastric lavage.
National Toxicology Program Studies · 1 Eintrag

... Toxicology and carcinogenicity studies were conducted by administering probenecid (>99% pure) in corn oil by gavage to groups of F344/N rats and B6C3F1 mice of each sex ... 5 days/wk ... for ... 2 yr. ... Doses of 0, 100, and 400 mg/kg were used for the 2 yr studies in rats and mice. These doses were administered once daily, 5 days/wk for up to 103 wk to groups of 50 males or 50 females of each species. Under the conditions of these 2 yr gavage studies, there was no evidence of carcinogenic activity of probenecid for male or female F344/N rats receiving 100 or 400 mg/kg in corn oil. There was no evidence of carcinogenic activity of probenecid for male B6C3F1 mice given 100 or 400 mg/kg probenecid in corn oil. There was some evidence of carcinogenic activity of probenecid for female B6C3F1 mice based on an increased incidence of hepatocellular adenomas.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Regulatorische Informationen

FDA Requirements · 2 Einträge

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl probenecid, approved on the basis of safety and effectiveness by FDA under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act.

Sicherheitsdaten

wgk
3
tsca
TSCA listed
ridadr
3249
hs_code
29350090
RTECS-Nr.
DG9400000
risk_code
22-40
hazard_code
Xn
safety_code
36/37-24/25
Speicherklasse
11 - Combustible Solids
Giftige Stoffe Daten
57-66-9(Hazardous Substances Data)
Hazard Classifications
Acute Tox. 4 Oral

At the proximal and distal tubules, probenecid competitively inhibits the secretion of many weak organic acids including penicillins, most cephalosporins, and some other beta-lactam antibiotics. In general, the net effect of probenecid on the plasma concentration of weak acids depends on the ratio of the amount of organic acid secreted by the kidneys to that amount filtered at the glomeruli. Thus, probenecid substantially increases plasma concentrations of acidic drugs eliminated principally by renal secretion, but increases plasma concentrations only slightly if the drug is eliminated mainly by filtration. Plasma concentrations of penicillins are often more than doubled by probenecid; the concentration of penicillin in the CSF is also increased. Probenecid also substantially increases plasma concentrations of most cephalosporins and some other beta-lactam antibiotics. In addition, half-lives of the penicillins and cephalosporins are prolonged and their volumes of distribution may be reduced by probenecid. ... The cellular mechanism(s) responsible for the inhibition of renal tubular transport by probenecid is not known. The drug may inhibit transport enzymes that require a source of high energy phosphate bonds and/or nonspecifically interfere with substrate access to protein receptor sites on the kidney tubules.

CSF concentrations of 5-hydroxyindoleacetic acid, homovanillic acid, cyclic adenosine monophosphate, and 4-hydroxy-3-methoxyphenylglycol are elevated following administration of probenecid. It has been proposed that probenecid blocks the active transport of these organic acids from the CSF into blood. Probenecid-induced elevations of homovanillic acid (a dopamine metabolite) in the CSF of patients with parkinsonian syndrome and of 5-hydroxyindoleacetic acid(a metabolite of serotonin) in the CSF of mentally depressed patients are substantially lower than those in healthy patients.

Biological Half-Life · 3 Einträge

6-12 hours

THE HALF-LIFE OF /PROBENECID/ IN PLASMA IS DOSE DEPENDENT AND VARIES FROM LESS THAN 5 HR TO MORE THAN 8 HR ... .

Following oral administration of 2 g of probenecid, plasma half-life of the drug ranges from 4-17 hr; the half-life decreases as the dose decreases from 2 g to 500 mg.

Metabolism/Metabolites · 5 Einträge

YIELDS P-DIPROPYLSULFAMOYLBENZOYL-BETA-D-GLUCURONIC ACID; P-(2-HYDROXYPROPYL N-PROPYLSULFAMOYL) BENZOIC ACID; P-(3-HYDROXYPROPYL N-PROPYLSULFAMOYL) BENZOIC ACID; & P-PROPYLSULFAMOYLBENZOIC ACID IN MAN. /FROM TABLE/

STRUCTURES OF ALL OF METAB OF PROBENECID IN RAT BILE & HUMAN URINE HAVE BEEN ELUCIDATED. PROPIONIC ACID HAS NOW BEEN IDENTIFIED AS ANOTHER PROBENECID METAB. MAJOR METABOLIC PATHWAYS INVOLVE SIDE-CHAIN OXIDATION & GLUCURONIDE CONJUGATION ... .

... BETA-GLUCURONIDES OF 2- & 3-HYDROXYLATED METAB & ACYL GLUCURONIDE OF PROBENECID PER SE HAVE NOW BEEN IDENTIFIED. ... THERE IS CONSIDERABLE SPECIES DIFFERENCE IN METABOLISM. IN RATS & MONKEYS OXIDATION IS FAVORED. ... IN DOGS CONJUGATION ... /IS/ MAJOR PATHWAY, WHEREAS IN MAN, OXIDATIVE ... PATHWAY ... IS AS IMPORTANT AS GLUCURONIDATION.

CHRONIC ADMIN OF DRUGS NOT ONLY STIMULATES METAB OF OTHER CMPD, BUT IN SOME INSTANCES PHARMACOLOGICAL OR TOXIC EFFECT OF A DRUG WHEN GIVEN CHRONICALLY, DIMINISHES, BECAUSE IT STIMULATES ITS OWN METABOLISM EXAMPLE OF DRUG THAT EXERT THIS EFFECT IN DOGS ... /IS/ ... PROBENECID ... .

For more Metabolism/Metabolites (Complete) data for PROBENECID (6 total), please visit the HSDB record page.

MeSH Pharmacological Classification · 2 Einträge

Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.

Gout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma.

Absorption, Distribution and Excretion · 6 Einträge

Excreted principally in the urine as monoacyl glucuronide and unchanged drug. Alkalinization of urine increases renal probenecid excretion.

PROBENECID IS COMPLETELY ABSORBED AFTER ORAL ADMIN. PEAK PLASMA CONCN ARE REACHED IN 2-4 HR. THE HALF-LIFE OF THE DRUG IN PLASMA IS DOSE DEPENDENT AND VARIES FROM LESS THAN 5 HR TO MORE THAN 8 HR.

BETWEEN 85 & 95% OF DRUG IS BOUND TO PLASMA ALBUMIN, LARGELY TO ALBUMIN. SMALL UNBOUND PORTION GAINS ACCESS TO GLOMERULAR FILTRATE; A MUCH LARGER PORTION IS ACTIVELY SECRETED BY PROXIMAL TUBULE.

IN SPITE OF ITS LOW PKA (3.4), HIGH LIPID SOLUBILITY OF UNDISSOCIATED FORM RESULTS IN VIRTUALLY COMPLETE ABSORPTION BY BACK DIFFUSION UNLESS URINE IS MARKEDLY ALKALINE. SMALL AMOUNT OF PROBENECID GLUCURONIDE APPEARS IN URINE.

... /ORG ACID CMPD SUCH AS PROBENECID /ARE/ NOT TAKEN UP SO AVIDLY BY /PARENCHYMATOUS OR RETICULO-ENDOTHELIAL TISSUES/ & EXHIBIT HIGHER PLASMA CONCN ... .

For more Absorption, Distribution and Excretion (Complete) data for PROBENECID (8 total), please visit the HSDB record page.

Cellular LocationsExtracellular

Verwendung und Herstellung

Uses · 2 Einträge

MEDICATION

Use (kg; approx.) in Germany (2009): >250

U.S. Imports · 2 Einträge

(1976) 6.15X10+6 GRAMS (PRINCPL CUSTMS DISTS)

(1978) 9.09X10+6 GRAMS (PRINCPL CUSTMS DISTS)

U.S. Production · 2 Einträge

(1976) PROBABLY GREATER THAN 9.08X10+5 GRAMS

(1978) PROBABLY GREATER THAN 9.08X10+5 GRAMS

Methods of Manufacturing · 2 Einträge

REACTION OF TOLUENE WITH CHLOROSULFONIC ACID FOLLOWED BY HYDROLYSIS AND OXIDATION YIELDS P-CARBOXYBENZENESULFONICACID, THEN TREATMENT OF THIS ACID WITH CHLOROSULFONIC ACID AND CONDENSATION WITH DI-N-PROPYLAMINE

PREPARATION FROM P-CARBOXYBENZENESULFONYL CHLORIDE & DIPROPYLAMINE.

Formulations/Preparations · 5 Einträge

PROBENECID (BENEMID, PROBALAN) IS MARKETED AS ORAL TABLETS (500 MG).

Oral Tablets, 500 mg, Benemid (scored), MSD; Probalan, Lannett; Tablets, film coated 500 mg.

Oral For suspension, Ampicillin (trihydrate) 3.5 g (of ampicillin) with Probenecid 1 g, Amplicillin and Probenecid Oral Suspension, Biocraft; Polycillin-BRB, Bristol-Myers; Probampacin, Goldline. /Ampicillin (Trihydrate) and Probenecid/

Oral Tablets 500 mg Probenecid and Colchincine 0.5 mg, ColBENEMID (scored), MSD; Col-Probenecid, Danbury, Goldline, United Research; Proben-C Rugby. /Probencid and Colchicine/

Tablets, 500 mg

Use ClassificationPharmaceuticals
General Manufacturing InformationBenzoic acid, 4-[(dipropylamino)sulfonyl]-: ACTIVE
Anwendungen · 2 Einträge

BeschreibungProbenecid is insoluble in water and acidic solutions but is soluble in alkaline solutions buffered to pH 7.4. Probenecid initially was synthesized as a result of studies in the 1940s on sulfonamides that indicated the sulfonamides decreased the renal clearance of penicillin, extending the half-life of penicillin as supplies diminished. Probenecid thus was initially used—and is still indicated—for that purpose. Probenecid promotes the excretion of uric acid by inhibiting the urate anion exchange transporter (URAT 1), decreasing the reabsorption of uric acid in the proximal tubules. The overall effect is to decrease plasma uric acid concentrations, thereby decreasing the rate and extent of urate crystal deposition in joints and synovial fluids. Within the series of N-dialkylsulfamyl benzoates from which probenecid is derived, renal clearance of these compounds is decreased as the length of the N-alkyl substituents is increased. Uricosuric activity increases with increasing size of the alkyl group in the series methyl, ethyl, and propyl.

VerwendenIt is a uricosuric drug, that is, it increases uric acid excretion in the urine. It is primarily used in treating gout and hyperuricemia. Probenecid was developed as an alternative to caronamide to competitively inhibit renal excretion of some drugs, thereby increasing their plasma concentration and prolonging their effects.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Natriumdichromat DihydratNatriumbromidToluol-4-sulfonamid1-Brompropan4-(Chlorsulfonyl)benzoesureDi-n-Propylamin

Nachgelagerte Produkte

Benzoic acid, 4-[(dipropylamino)sulfonyl]-, chloromethyl ester

Ergänzende Hinweise

DefinitionChEBI: A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.